ESMINT Society

11/09/2026

🎥 ESMINT TV Studio |

How can we better understand DCI – and design better trials to address it?

Adrien Guenego and Paul Bhogal explore the complex mechanisms behind delayed cerebral ischemia, from endothelial dysfunction and microthrombosis to platelet-related pathways.

They also discuss why translational thinking, diverse perspectives and a broader view of disease mechanisms may be key to developing the next generation of neurointerventional trials.

▶️ Watch the full conversation: https://buff.ly/35roPb6
– and explore more ESMINT TV Studio sessions from : https://buff.ly/L4cfCS8

Moderator: Dr. Adrien Guenego

10/09/2026

🎥 ESMINT TV Studio |

Can we make the next MDVO trial smarter?

Adrien Guenego and Marios Psychogios discuss what we can learn from previous MDVO trials – from patient selection and equipoise to adaptive trial designs and the role of NIHSS.

What needs to change to generate clearer answers from the next generation of MDVO trials?

▶️ Watch the full conversation – and explore more ESMINT TV Studio sessions from : https://buff.ly/G1KivcV

Moderator: Dr. Adrien Guenego

09/09/2026

What a Congress. What a community. 🧡

brought our community together in Marseille for three days of science, debate, learning, collaboration and connection. None of it would have been possible without the many people who contributed.

A huge thank you to our 2026 Congress President Franziska Dorn; Vice-Presidents Ivan Vukasinovic, Kamil Zelenak and Luca Valvassori; our Programme Committee, Scientific Congress Committee, speakers, moderators, chairs, panellists, Coffee & Cases and Coff-ePoster contributors.

Thank you to our ESMINT leadership and committees, EYMINT and ETMINT, and to our sister societies EANS, ESO and SNIS for bringing their perspectives and communities to Marseille.

Thank you also to our platinum and gold sponsors, exhibitors and start-ups; everyone behind the ESMINT TV Studio, WIN activities, Morning Run and Networking Event; our award, grant, EDNI and EDSI recipients; AIM International and all teams and partners involved in making the Congress happen; the Palais du Pharo team; and Denis for capturing so many unforgettable moments.

And most importantly, thank you to everyone who joined us in Marseille. Whether you presented, asked a question, joined a discussion, met a colleague, shared an idea or simply came to learn, you were part of .

The success of ESMINT 2026 is thanks to you. 🧡

And now… who is ready to do it all again?

📅 8–10 September 2027
📍 Marseille, Palais du Pharo
👤 Congress President: Jan-Hendrik Buhk

See you at !

07/09/2026

Day 2 of in pictures 📸

Another full day of science, exchange and new perspectives in Marseille.

From a look inside the realities of working in INR and our Joint Session with the European Stroke Organisation (ESO) to Alejandro Berenstein’s inspirational talk on the future of neurointervention and new frontiers in neurooncology, Day 2 explored both the challenges of today and where our field may be heading next.

We also celebrated achievements across our community with the ESMINT Awards, Research Grant Awards and Diploma Ceremony, before closing the scientific programme with ongoing and final trials and ESMINT-endorsed studies.

Beyond the Main Lecture Hall, there was plenty happening too: Coffee & Cases continued the conversation in a more informal setting, our ESMINT TV Studio welcomed experts for interviews and discussions, and ETMINT brought technicians, nurses and radiographers together for its parallel programme.

Day 2 also started on the move, with our Morning Run & Yoga bringing the ESMINT community together before the scientific programme began. Thank you to iVascular for supporting the activity.

And between it all: conversations, reunions and connections throughout the Palais du Pharo.

Here are some impressions from Day 2.

📸 Thank you to Denis Abbonato-Bei

Isabel Fragata, Adrien Guenego, Helena Guerreiro, Marc Ribo, Franziska Dorn, Christian Taschner, Mohamed Aggour, Michael Chen, Victor Schulze-Zachau, Francesco Diana, Markus Möhlenbruch, Razvan Radu, Wim van Zwam, Senta Frol, Alen Gobulovic, Aymeric Rouchaud, Marco Ciuffreda, Rasmus Holmboe Dahl, Alejandro Berenstein, Laurent Spelle

04/09/2026

Can fusion imaging make thrombectomy faster and more successful?

In “I Can See Clearly Now – The Blur Is Gone” at , Johan Wassélius presented an observational study of 347 consecutive patients undergoing endovascular thrombectomy, including 68 procedures using fusion of pre-treatment CT angiography with live X-ray imaging.

With fusion guidance, successful recanalization was achieved in 100% of patients compared with 86% without fusion imaging. First-pass recanalization was also more frequent (72% vs 49%), while median time from groin puncture to recanalization was shorter (33 vs 43 minutes).

The findings suggest that fusion imaging may improve procedural guidance, first-pass success and overall recanalization without adding delay.

Prospective randomised studies are needed to confirm these results.

04/09/2026

What have clinical trials actually demonstrated about middle meningeal artery embolization, and what have they not?

At , Jildaz Caroff reviewed six randomised trials involving 2,153 patients with chronic subdural haematoma. The evidence shows that adjunctive MMA embolization reduces radiological recurrence and reoperation, with acceptable procedural safety.

But the trials have not demonstrated improvements in functional outcome, quality of life or mortality, and functionally dependent patients were not included.

His review of ten ongoing randomised trials, involving a further 4,471 patients, identified the same gap: none uses functional outcome as its primary endpoint.

The key message: MMA embolization has proven that it can prevent a reoperation, but not yet that it changes what happens to the patient afterwards. A real advance, and an important question for future RCTs.

04/09/2026

How should antiplatelet therapy be managed in pediatric neurointervention?

In Scientific Abstracts Session IV at , Sophia Hohenstatt presented a multisociety expert consensus guideline developed by ESMINT, ESNR, IPSO, SNIS and WFITN.

The recommendations address age- and weight-adapted dosing, elective stenting and flow diversion, urgent or bailout stenting, intraprocedural thrombus management, parenteral bridging and platelet-function testing.

The consensus provides a practical framework for current practice while recognising that pediatric-specific evidence remains limited.

04/09/2026

First multicenter experience with a fibrin-heparin-coated carotid stent in acute stroke EVT.

In Scientific Abstracts Session IV at , Gabriel Broocks presented data from 92 patients treated with the CARESTO® heal stent across four neurointerventional centers. Deployment was successful in 100%, mTICI ≥2b reperfusion was achieved in 95.7%, and early in-hospital stent occlusion occurred in 1.1%.

The results support further evaluation of coated stent technology for emergent extracranial ICA reconstruction during stroke thrombectomy.

04/09/2026

Intracranial atherosclerotic disease does not look the same everywhere.

In “Two Worlds, One Disease: Global Lessons in ICAD” at , Sirintara Singhara Na Ayudhaya presented the Asian perspective, where ICAD is considerably more prevalent and represents an important cause of stroke.

Her presentation highlighted differences in disease patterns, risk factors and differential diagnoses, including intracranial dissection and moyamoya disease, as well as the role of risk-factor control, medical therapy and selected endovascular management.

04/09/2026

Can haemodynamic assessment improve patient selection for endovascular treatment of intracranial atherosclerotic stenosis?

In “Trial and Trial Again – Ongoing & Final Trials” at , Yu Zhou on behalf of Pengfei Yang presented ICAS-MT, a randomized controlled trial comparing endovascular and medical therapy using angiography-derived fractional flow (Angio-FF) to guide selection.

The study builds on the premise that haemodynamic metrics may identify high-risk patients more effectively than stenosis severity alone.